Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
November 11, 2024 08:00 ET
|
Autonomix Medical, Inc.
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6...
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
November 01, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
October 31, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial
October 28, 2024 08:00 ET
|
Autonomix Medical, Inc.
100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
October 25, 2024 11:32 ET
|
SeaStar Medical Holding Corporation
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury ...
Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
October 25, 2024 11:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
October 25, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury ...
SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial
October 23, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers
October 22, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Autonomix Announces Reverse Stock Split
October 22, 2024 08:30 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...